Michael Barbella, Managing Editor05.07.24
Former U.S. Food and Drug Administration (FDA) senior officials John Taylor and Michele Dougherty, Ph.D., have joined ELIQUENT Life Sciences' executive ranks. The company hired Taylor to lead its Quality & Compliance Practice, and Dougherty to head its Regulatory Affairs Practice.
ELIQUENT’s integrated services deliver the answers and solutions to help global life sciences firms gain and maintain market authorization for their products. The ELIQUENT team works cross-functionally to support pharmaceutical, biotechnology, medical device, combination product, and cosmetics innovators across therapeutic modalities, phase-based pathways, and major global markets.
Taylor has more than 30 years of regulatory experience. During his 20-year career at the FDA, he served in multiple leadership positions, including as Acting Deputy Principal Commissioner, FDA Counselor to the Commissioner, Acting Deputy Commissioner for Global Regulatory Operations and Policy, and Associate Commissioner for Regulatory Affairs. Taylor’s experience also includes roles within regulated industry, including service as executive vice president for Health at the Biotechnology Industry Organization (BIO) and as divisional vice president for Federal Government Affairs at Abbott. Most recently, Taylor worked for 10 years as president and principal of Compliance & Regulatory Affairs at Greenleaf Health, a legacy brand of ELIQUENT Life Sciences.
Taylor earned his J.D. from the College of William and Mary and is a graduate of Pennsylvania State University.
A 10-year veteran of FDA, Dougherty’s career includes more than 15-years of regulatory experience across the product quality lifecycle, including her most recent role as president of DataRevive, a legacy brand of ELIQUENT Life Sciences. Dougherty joined FDA in 2008 as a product quality reviewer in the Office of Biotechnology Products (OBP). During her FDA tenure, she developed expertise across the manufacturing and product quality lifecycle and held multiple leadership roles, including OBP Team Lead and Review Chief. Dougherty managed a diverse portfolio of products including monoclonal antibodies, antibody-drug conjugates, antibody cocktails, growth factors, enzymes, and biosimilar products. Dougherty's biosimilars expertise is enhanced by her role on the Therapeutic Biologics and Biosimilar Staff in the FDA’s Office of New Drugs, where she focused on supporting review of biosimilar products and participated in guidance and policy initiatives related to the biosimilar development pathway.
Dougherty earned her Ph.D. from Georgetown University and completed her post-doctoral training in the Laboratory of Cell and Developmental Signaling at the National Cancer Institute.
ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ELIQUENT’s growth is supported by GHO Capital, the European specialist investor in healthcare.
ELIQUENT’s integrated services deliver the answers and solutions to help global life sciences firms gain and maintain market authorization for their products. The ELIQUENT team works cross-functionally to support pharmaceutical, biotechnology, medical device, combination product, and cosmetics innovators across therapeutic modalities, phase-based pathways, and major global markets.
Taylor has more than 30 years of regulatory experience. During his 20-year career at the FDA, he served in multiple leadership positions, including as Acting Deputy Principal Commissioner, FDA Counselor to the Commissioner, Acting Deputy Commissioner for Global Regulatory Operations and Policy, and Associate Commissioner for Regulatory Affairs. Taylor’s experience also includes roles within regulated industry, including service as executive vice president for Health at the Biotechnology Industry Organization (BIO) and as divisional vice president for Federal Government Affairs at Abbott. Most recently, Taylor worked for 10 years as president and principal of Compliance & Regulatory Affairs at Greenleaf Health, a legacy brand of ELIQUENT Life Sciences.
Taylor earned his J.D. from the College of William and Mary and is a graduate of Pennsylvania State University.
A 10-year veteran of FDA, Dougherty’s career includes more than 15-years of regulatory experience across the product quality lifecycle, including her most recent role as president of DataRevive, a legacy brand of ELIQUENT Life Sciences. Dougherty joined FDA in 2008 as a product quality reviewer in the Office of Biotechnology Products (OBP). During her FDA tenure, she developed expertise across the manufacturing and product quality lifecycle and held multiple leadership roles, including OBP Team Lead and Review Chief. Dougherty managed a diverse portfolio of products including monoclonal antibodies, antibody-drug conjugates, antibody cocktails, growth factors, enzymes, and biosimilar products. Dougherty's biosimilars expertise is enhanced by her role on the Therapeutic Biologics and Biosimilar Staff in the FDA’s Office of New Drugs, where she focused on supporting review of biosimilar products and participated in guidance and policy initiatives related to the biosimilar development pathway.
Dougherty earned her Ph.D. from Georgetown University and completed her post-doctoral training in the Laboratory of Cell and Developmental Signaling at the National Cancer Institute.
ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ELIQUENT’s growth is supported by GHO Capital, the European specialist investor in healthcare.